Discoverer of Klotho gene further strengths KLTO Scientific Advisory BoardNEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KLTO), a leading biotechnology company focused on developing cell and ...

(Alliance News) - Syncona Ltd on Wednesday noted positive trial results for a portfolio company's gene therapy aimed at treating people with Gaucher's disease.

Advancements in organoid technology are crucial for Parkinson's disease research, providing human-relevant models for ...

The incubator is designed to draw cell and gene therapy researchers and drugmakers to work at the hub, where they can develop ...

A high dose of the investigational gene therapy AAV-GAD, which delivers the glutamic acid decarboxylase ( GAD) gene to the ...

Knowledge on the genetic basis of Parkinson's disease has grown tremendously since the discovery of the first monogenic form, ...

MJFF launches initiative to expedite development of LRRK2-targeted therapies and biomarkers for Parkinson’s disease: New York Saturday, October 19, 2024, 11:00 Hrs [IST] The Mic ...

Here's a recap of the week’s most important stories.

The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s ...

Capsida Biotherapeutics Inc. presented preclinical data for a new next-generation gene supplementation therapy candidate, CAP-003, for Parkinson’s disease (PD) patients with GBA1 mutations (PD-GBA).

The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.